Structure Therapeutics has released positive results from a mid-stage clinical trial of its experimental oral pill alenigliprone for the treatment of obesity.[2][3] Patients taking the 120 mg daily dose achieved an average weight loss of 11.3% compared to placebo after 36 weeks.[2][3] At the higher dose of 240 mg, weight loss increased to 15.3%.[2][3] Of the participants on the 120 mg dose, 86% of patients achieved at least 5% weight loss and 70% of patients achieved at least 10% weight loss.[3] The most common side effects were gastrointestinal problems, including nausea and vomiting, with 10.4% of participants discontinuing treatment due to side effects.[2][3] The study did not report any cases of liver damage or persistent elevation of liver enzymes.[3] The company plans to meet with the FDA in the first half of 2026 to finalize the Phase 3 study design.[3]